Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2011-08-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
第四届董事会第二十一次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Beijing SL Pharmaceutical Co., Ltd. It details the decision to invest in a joint venture company in Canada, including specifics of the investment amount, shareholding structure, and cooperation partner. The document is titled as a board meeting resolution announcement and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release. It is not a proxy statement or voting result announcement. The content focuses on a board decision regarding a capital investment and joint venture formation, which is a management/board information update. The document length is short (1001 characters), consistent with an announcement rather than a full report. Therefore, the appropriate classification is Board/Management Information (MANG).
2011-08-13 Chinese
独立董事关于对外（境外）投资的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding an overseas investment proposal by the company. It discusses the board meeting approval of the investment, the strategic rationale, and compliance with company law and regulations. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal opinion related to a specific corporate action rather than a full report or announcement of financial results. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is also not a regulatory filing or certification. The content aligns best with Board/Management Information (MANG) as it involves board-level approval and independent director opinions on a significant investment decision.
2011-08-13 Chinese
2011年半年度财务报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as "2011 年半年度财务报告" which translates to "2011 Half-Year Financial Report". It contains detailed financial statements including balance sheets, income statements, cash flow statements, and changes in equity for the period ending June 30, 2011. The content is comprehensive and includes actual financial data and analysis for a period shorter than a full fiscal year (half-year). This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is IR with high confidence. H1 2011
2011-07-30 Chinese
独立董事对公司累计和当期对外担保及关联方资金占用情况的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of Beijing SL Pharmaceutical Co., Ltd. regarding the company's external guarantees and related party fund occupation as of June 30, 2011. It references regulatory notices from the China Securities Regulatory Commission and confirms compliance with disclosure and approval procedures. The document is short (521 characters) and serves as a formal statement or certification rather than a full report. It does not contain financial statements or detailed financial analysis. This fits best with the category of Regulatory Filings (RNS), which includes attestations and confirmations that do not constitute full reports.
2011-07-30 Chinese
2011年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2011 年半年度报告摘要" which translates to "Beijing Shuanglu Pharmaceutical Co., Ltd. 2011 Semi-Annual Report Summary." It contains detailed financial data for the first half of 2011, including balance sheets, profit and loss data, shareholder information, and management discussion. The document explicitly states it is a half-year report summary and includes comprehensive financial statements and analysis for the period January to June 2011. The length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. H1 2011
2011-07-30 Chinese
2011年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2011 年半年度报告全文" which translates to "2011 Semi-Annual Report Full Text." It contains detailed financial data for the first half of 2011, including main accounting data, financial indicators, shareholder information, management and board details, and a comprehensive financial report section. The report explicitly states it is a half-year report (半年度报告), covering the period January to June 2011, with actual financial figures and analysis. The length is substantial (15,000 characters), and it includes detailed financial statements and management discussion. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2011
2011-07-30 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.